Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Brad Bernstein, managing director at UBS Private Wealth Management breaks down the state of the U.S. economy and what to expect from Fed policy from the rest of the year.
SpaceX Investor Chad Anderson discusses Starship's latest test flight, what's next, and why he thinks Elon Musk's leadership sent the company in the right direction.
Dilip Rao, CEO of Sharebite, explains how his startup wants to normalize companies feeding their workers, the role of the private sector in public concerns, and more.
Athlete compensation, player unions and realignment dominate discussions — everything in college sports is open for discussion, interpretation and adjustment.
Sola Mahfouz and Malaina Kapoor, authors of 'Defiant Dreams: The Journey of an Afghan Girl Who Risked Everything for Education' discuss how Sola overcame the Taliban to get an education.
